JOP20200078A1 - أجسام مضادة خاصة بـ cd47 وpd-l1 - Google Patents

أجسام مضادة خاصة بـ cd47 وpd-l1

Info

Publication number
JOP20200078A1
JOP20200078A1 JOP/2020/0078A JOP20200078A JOP20200078A1 JO P20200078 A1 JOP20200078 A1 JO P20200078A1 JO P20200078 A JOP20200078 A JO P20200078A JO P20200078 A1 JOP20200078 A1 JO P20200078A1
Authority
JO
Jordan
Prior art keywords
antibodies
relates
antibodies specific
antigen
present
Prior art date
Application number
JOP/2020/0078A
Other languages
English (en)
Inventor
Kirill Vladimirovich Solovyev
Valery Vladimirovich Solovyev
Timofey Aleksandrovich Nemankin
Dmitry Valentinovich Morozov
Andrei Borisovich Ulitin
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of JOP20200078A1 publication Critical patent/JOP20200078A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

أجسام مضادة خاصة بـ CD47 وPD-L1 الملخص يتعلق الاختراع الحالي بمجال الهندسة الحيوية، وتحديداً بأجسام مضادة أو شظايا منها رابطة لمولد الضد، وباستخدامها. وبشكل أكثر تحديداً، يتعلق الاختراع الحالي بأجسام مضادة والتي ترتبط على وجه الخصوص بـ CD47 وPD-L1. يتعلق الاختراع أيضاً بحمض نووي والذي يقوم بترميز الجسم المضاد المحدد أو لشظية منه رابطة لمولد الضد، بناقل التعبير الوراثي، وبطريقة لإنتاج الجسم المضاد، وباستخدام الأجسام المضادة والتركيبات المذكورة سابقاً في علاج السرطان.
JOP/2020/0078A 2017-10-03 2018-10-03 أجسام مضادة خاصة بـ cd47 وpd-l1 JOP20200078A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EA201791961A EA039662B1 (ru) 2017-10-03 2017-10-03 Антитела, специфичные к cd47 и pd-l1
PCT/EA2018/050001 WO2019068302A1 (ru) 2017-10-03 2018-10-03 Антитела, специфичные к cd47 и pd-l1

Publications (1)

Publication Number Publication Date
JOP20200078A1 true JOP20200078A1 (ar) 2020-04-30

Family

ID=65994976

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0078A JOP20200078A1 (ar) 2017-10-03 2018-10-03 أجسام مضادة خاصة بـ cd47 وpd-l1

Country Status (21)

Country Link
US (1) US11840567B2 (ar)
EP (1) EP3693390A4 (ar)
JP (2) JP2020535839A (ar)
KR (1) KR20200058542A (ar)
CN (1) CN111801352A (ar)
AR (1) AR113342A1 (ar)
AU (1) AU2018345458A1 (ar)
BR (1) BR112020006706A2 (ar)
CA (1) CA3078413A1 (ar)
CL (1) CL2020000919A1 (ar)
CO (1) CO2020004199A2 (ar)
EA (1) EA039662B1 (ar)
EC (1) ECSP20024555A (ar)
JO (1) JOP20200078A1 (ar)
MA (1) MA49599B1 (ar)
MX (1) MX2020004027A (ar)
PE (1) PE20210460A1 (ar)
PH (1) PH12020550214A1 (ar)
TW (1) TWI768129B (ar)
WO (1) WO2019068302A1 (ar)
ZA (1) ZA202002047B (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017336867B2 (en) 2016-09-29 2024-03-14 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
EP3533804A4 (en) 2016-11-18 2020-06-17 Beijing Hanmi Pharmaceutical Co., Ltd. BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF
KR20200093639A (ko) * 2017-12-04 2020-08-05 북경한미약품 유한공사 천연 항체 구조-유사 헤테로다이머 형태의 항 pd-l1/항 cd47 이중특이성 항체 및 이의 제조
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
EP3564263A1 (en) * 2018-05-03 2019-11-06 Universitätsklinikum Hamburg-Eppendorf Fusion proteins comprising a cell surface marker specific vhh
US20220289848A1 (en) * 2019-05-17 2022-09-15 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereof
KR20220036998A (ko) * 2019-06-25 2022-03-23 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항 cd47/pd-l1 이중특이성 항체를 포함하는 제제, 이의 제조 방법 및 용도
CN114072426B (zh) * 2019-07-08 2024-01-26 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用
CA3156160A1 (en) * 2019-09-27 2021-04-01 Beijing Starmab Biomed Technology Ltd. Monospecific and multi-specific antibodies
CN112745392B (zh) * 2019-10-30 2022-07-01 上海洛启生物医药技术有限公司 抗pd-l1/cd47双特异性抗体及其用途
IL293926A (en) * 2019-12-17 2022-08-01 Pfizer Antibodies unique to d47, pd-l1 and their uses
CN115315445A (zh) * 2020-02-12 2022-11-08 上海诗健生物科技有限公司 一种靶向人cd47的单域抗体及其用途
WO2022057939A1 (en) * 2020-09-21 2022-03-24 I-Mab Biopharma Co., Ltd. Pharmaceutical composition comprising cd47 antibody and pd-1/pd-l1 inhibitor
US20240067728A1 (en) * 2020-11-06 2024-02-29 Bio-Thera Solutions, Ltd. Bispecific antibody and use thereof
EP4253415A1 (en) * 2020-11-12 2023-10-04 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor
KR20220118961A (ko) * 2021-02-19 2022-08-26 (주)샤페론 Cd47에 대한 단일 도메인 항체 및 이의 용도
KR20220118963A (ko) * 2021-02-19 2022-08-26 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도
WO2022177393A1 (ko) * 2021-02-19 2022-08-25 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
CN117279948A (zh) * 2021-05-07 2023-12-22 益免安协公司 与cd47和pd-l1特异性结合的双特异性抗体
AR126185A1 (es) * 2021-06-21 2023-09-27 Joint Stock Company “Biocad” Anticuerpo biespecífico aislado que se une específicamente a cd47 y pd-l1
CN115702931A (zh) * 2021-08-06 2023-02-17 百奥泰生物制药股份有限公司 抗pd-l1/cd47双特异抗体在治疗疾病中的应用
WO2023051680A1 (zh) * 2021-09-30 2023-04-06 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体
WO2023154730A2 (en) * 2022-02-09 2023-08-17 Exelixis, Inc. Multispecific binding agents and uses thereof
KR20230163305A (ko) * 2022-05-19 2023-11-30 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도
WO2024022384A1 (en) * 2022-07-28 2024-02-01 Shenzhen Enduring Biotech , Ltd. Peg based anti-cd47/anit-pd-l1 bispecific antibody-drug conjugate

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
JPH06500011A (ja) 1990-06-29 1994-01-06 ラージ　スケール　バイオロジー　コーポレイション 形質転換された微生物によるメラニンの製造
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
US6808710B1 (en) 1999-08-23 2004-10-26 Genetics Institute, Inc. Downmodulating an immune response with multivalent antibodies to PD-1
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
DE50106330D1 (de) 2000-08-18 2005-06-30 Linde Ag Verfahren zur herstellung einer luftzerlegungsanlage
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP2262837A4 (en) * 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
SI2376535T1 (sl) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
HUE060541T2 (hu) 2010-05-14 2023-03-28 Univ Leland Stanford Junior Humanizált és kiméra monoklonális CD47 elleni ellenanyagok
SI2812443T1 (sl) 2012-02-06 2019-10-30 Inhibrx Inc Protitelesa CD47 in postopki za njihovo uporabo
JP6392770B2 (ja) * 2012-12-03 2018-09-19 ノビミューン エスアー 抗ｃｄ４７抗体およびその使用方法
AU2013359167B2 (en) 2012-12-12 2018-08-23 Arch Oncology, Inc. Therapeutic CD47 antibodies
GB201300706D0 (en) 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
KR102276974B1 (ko) 2013-02-06 2021-07-13 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
CU20170052A7 (es) * 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
JP2018535692A (ja) 2015-09-21 2018-12-06 エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 抗ｃｄ４７抗体及び使用方法
RU2665790C1 (ru) * 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1

Also Published As

Publication number Publication date
MA49599B1 (fr) 2023-05-31
BR112020006706A2 (pt) 2020-10-06
TW201922781A (zh) 2019-06-16
RU2020115122A (ru) 2021-10-29
CL2020000919A1 (es) 2020-10-16
MA49599A1 (fr) 2021-01-29
PE20210460A1 (es) 2021-03-08
AU2018345458A2 (en) 2020-05-21
JP2023130455A (ja) 2023-09-20
MX2020004027A (es) 2020-08-13
EP3693390A1 (en) 2020-08-12
ECSP20024555A (es) 2020-06-30
AR113342A1 (es) 2020-04-22
RU2020115122A3 (ar) 2021-10-29
WO2019068302A1 (ru) 2019-04-11
US11840567B2 (en) 2023-12-12
KR20200058542A (ko) 2020-05-27
JP2020535839A (ja) 2020-12-10
EA201791961A1 (ru) 2019-04-30
PH12020550214A1 (en) 2021-02-15
EP3693390A4 (en) 2021-11-03
CO2020004199A2 (es) 2020-04-24
EA039662B1 (ru) 2022-02-24
AU2018345458A1 (en) 2020-05-14
ZA202002047B (en) 2022-08-31
CA3078413A1 (en) 2019-04-11
TWI768129B (zh) 2022-06-21
CN111801352A (zh) 2020-10-20
US20200270345A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
PH12017500890A1 (en) Antibody drug conjugates
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
NZ766660A (en) Anti-pd-l1 antibodies
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
NZ728688A (en) Anti-pd-1 antibodies
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
PH12019502298A1 (en) Monoclonal antibody to pd-l1
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20
UY37915A (es) Anticuerpos específicos para cd47 y pd-l1